NEW YORK (GenomeWeb) – Biocartis and Fast-track Diagnostics announced on Wednesday that they have formed a strategic collaboration to develop a range of multiplex tests for infectious diseases.
Under the arrangement, the companies will develop tests based on Fast-track's PCR-based infectious disease menu for use on Biocartis' Idylla automated molecular diagnostics platform. The first assay to be developed is expected to be a multiplex respiratory panel for the detection of viral and bacterial targets in upper respiratory tract infections.
Additional terms of the deal were not disclosed.
"By combining Fast-track Diagnostics' expertise and compelling portfolio of multiplex PCR panels with the multiplex capabilities and unique features of our Idylla system, we have formed a powerful combination to create tests that can identify multiple disease-driving pathogens from a patient sample," Erik Vossenaar, vice president of business development at Biocartis, said in a statement.